JPH01180825A - Agent for infectious disease - Google Patents
Agent for infectious diseaseInfo
- Publication number
- JPH01180825A JPH01180825A JP63001068A JP106888A JPH01180825A JP H01180825 A JPH01180825 A JP H01180825A JP 63001068 A JP63001068 A JP 63001068A JP 106888 A JP106888 A JP 106888A JP H01180825 A JPH01180825 A JP H01180825A
- Authority
- JP
- Japan
- Prior art keywords
- infectious disease
- agent
- phenyl
- compound
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000035473 Communicable disease Diseases 0.000 title claims abstract description 8
- 208000015181 infectious disease Diseases 0.000 title abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 abstract description 11
- 244000005700 microbiome Species 0.000 abstract description 6
- 241000233866 Fungi Species 0.000 abstract description 4
- 241000191940 Staphylococcus Species 0.000 abstract description 3
- 241000606161 Chlamydia Species 0.000 abstract description 2
- 241000589565 Flavobacterium Species 0.000 abstract description 2
- 241000204031 Mycoplasma Species 0.000 abstract description 2
- 241000606701 Rickettsia Species 0.000 abstract description 2
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 description 13
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 150000001782 cephems Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〈産業上の利用分野〉
本発明は、２−フェニル−１，２−ベンゾイソセレナゾ
ール−３（２Ｎ）−オン（以下、化合物Ａと称す）又は
その生理学的許容塩を有効成分とする感染症用剤に関す
る。Detailed Description of the Invention <Industrial Application Field> The present invention relates to 2-phenyl-1,2-benzisoselenazol-3(2N)-one (hereinafter referred to as compound A) or its physiologically acceptable This invention relates to an agent for infectious diseases containing salt as an active ingredient.
（従来の技術〉
ダラム陰性菌にも抗菌域をひろげた第三世代セフェム系
抗生物質が感染症の治療に使用されるようになってから
セフェム系抗生物質に対し耐性を示す黄色ブドウ球菌い
わゆるメシチリン耐性ブドウ球菌（以下、ＩＩＩＲ５Ａ
）による感染症が増大してきている。そして現在では、
臨床で分離されたブドウ球菌の約３鴎又はそれ以上がＭ
Ｒ５Ａであるという報告もある。ＭＲ５Ａは殆どのβラ
クタム系抗生物質に対して耐性があり、又最近使用され
出したニューキノロン系合成抗菌剤に対しても耐性を示
す。(Conventional technology) Since third-generation cephem antibiotics, which have expanded their antibacterial range to include Durham-negative bacteria, have been used to treat infections, Staphylococcus aureus, which has become resistant to cephem antibiotics, has become known as methicillin. Resistant Staphylococcus (hereinafter referred to as IIIR5A)
) infections are increasing. And now,
Approximately 3 or more of the clinically isolated Staphylococci are M.
There are also reports that it is R5A. MR5A is resistant to most β-lactam antibiotics, and also shows resistance to new quinolone synthetic antibacterial agents that have recently been used.
その他ミノマイシン、エリスロマイシン等の抗生物質に
対しても抵抗性を示すＭＲ５Ａが出現しきている。MR5A that is resistant to other antibiotics such as minomycin and erythromycin has also appeared.
このようなＭＲ５Ａに対し抗菌活性を示す薬剤としては
りファンビシン、バンコマイシン等があげられるが、こ
れらの薬剤に対しても耐性を示すＭＲ５Ａが出現すると
推定される。故に、ＭＲ５Ａに対し抗菌活性を示し、且
つ従来の化学療法剤とは作用機序の異なる薬剤の開発が
望まれる。Drugs that exhibit antibacterial activity against such MR5A include funvicin, vancomycin, and the like, but it is presumed that MR5A that is resistant to these drugs will also appear. Therefore, it is desired to develop a drug that exhibits antibacterial activity against MR5A and has a different mechanism of action from conventional chemotherapeutic agents.
又、化合物Ａが有する作用としてはグルタチオンペルオ
キシダーゼ様抗酸化作用および抗炎症作用が知られてい
る［バイオケミカル ファーマコロジー、ＶｏｌＪ３．
ＮＯ，２０，３２３５−３２３９，３２４１−３２４
５（１９８４）］。しかしながら、これらの作用は抗菌
活性とは何ら関連性を有するものではない。In addition, Compound A is known to have glutathione peroxidase-like antioxidant action and anti-inflammatory action [Biochemical Pharmacology, Vol. J3.
NO, 20, 3235-3239, 3241-324
5 (1984)]. However, these effects have no relation to antibacterial activity.
〈発明が解決しようとする問題点〉
本発明者らは、ＭＲＳＡに対し抗菌活性を示す薬剤を見
出すべく鋭意検討した結果、化合物ＡがＭＲＳＡを含む
種々の微生物に対し抗菌活性を示すことを見出し本発明
を完成した。<Problems to be Solved by the Invention> As a result of intensive studies to find a drug that exhibits antibacterial activity against MRSA, the present inventors discovered that Compound A exhibits antibacterial activity against various microorganisms including MRSA. The invention has been completed.
〈発明の構成〉
本発明は、化合物Ａ又はその生理学的許容塩を有効成分
とする感染症用剤に関するものである。<Configuration of the Invention> The present invention relates to an agent for infectious diseases containing Compound A or a physiologically acceptable salt thereof as an active ingredient.
化合物Ａが有効性を示す感染症としてはダラム陰性菌、
ダラム陽性菌、真菌、マイコプラズマ、リケッチア、ク
ラミジア等の微生物による感染症を、好ましくはダラム
陰性菌、ダラム陽性菌、真菌による感染症を、特に好ま
しくはフラボバクテリウム メニンゴスペティカム（Ｆ
ｌａｖｏｂａｃｔｅｒｉｕｍｍｅｎｉｎｇｏｓｐｅｔｉ
ｃｕｍ ） 、ＭＲＳＡ、黄色ブドウ球菌（Ｓｔａ −
ｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）、スタフィロ
コッカス エビデルミゾイス（Ｓｔａｐｈｙｌｏｃｏｃ
ｃｕｓ ｅｐｉｄｅｒｍｉｄｉｓ）、ストレプトコッカ
ス フェカリス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｆａｅｃ
ａｌｉｓ） 、キャンディダ アルビカンス（Ｃａｎ
−ｄｉｄａ ａｌｂｉｃａｎｓ）等の菌類による感染症
をあげることができる。Infectious diseases for which Compound A is effective include Durham-negative bacteria,
Infections caused by microorganisms such as Durham-positive bacteria, fungi, mycoplasma, rickettsia, and chlamydia, preferably infections caused by Durham-negative bacteria, Durham-positive bacteria, and fungi, and particularly preferably Flavobacterium meningospeticum (F
lavobacterium meningospeti
cum), MRSA, Staphylococcus aureus (Sta-
phylococcus aureus), Staphylococcus evidermizois
Streptococcus faecalis
alis), Candida albicans (Can
-dida albicans) and other fungal infections.
本発明の医薬にかかわる製剤型としては、錠剤、カプセ
ル剤、散剤、顆粒剤、シロップ剤、注射剤等をあげるこ
とができ、これらの製剤は化合物Ａに賦形剤、結合剤、
崩壊剤、溶解剤等の添加剤を組み合わせて公知の製剤技
術を用いることにより製造することができる。製剤の具
体的処方例を以下に示す。The pharmaceutical formulations of the present invention include tablets, capsules, powders, granules, syrups, injections, etc., and these formulations contain Compound A, excipients, binders,
It can be manufactured by combining additives such as disintegrants and solubilizers and using known formulation techniques. Specific formulation examples of the preparation are shown below.
錠剤：
化合物Ａ ５０ ｍｇカルボキシ
メチルセルロース ２５ ｍｇでんぷん
５ ｍｇ結晶セルロース ４０
ｍｇステアリン酸マグネシウム ２ ｍｇ計
１２２ ｍｇ化合物Ａは
通常経口又は非経口投与され、その投与量は、経口投与
の場合通常成人１人当たり１００〜１０００ｍｇ／日、
好ましくは２００〜３００ｍｇ ７日の範囲であり、患
者の症状に応じて適宜増減すればよい。Tablet: Compound A 50 mg carboxymethyl cellulose 25 mg starch
5 mg crystalline cellulose 40
mg magnesium stearate 2 mg meter
122 mg Compound A is usually administered orally or parenterally, and the dosage is usually 100 to 1000 mg/day per adult for oral administration.
The dose is preferably 200 to 300 mg for 7 days, and may be increased or decreased as appropriate depending on the patient's symptoms.
化合物Ａの毒性は、マウスおよびラットに経口又は腹腔
内投与で検討した結果、下記のＬｏｓｏ（ｍｇ／ｋｇ）
値で示されているように極めて低毒性のものであり、又
高用量投与時の所見についても副作用的に問題となるも
のはなんら認められなかった。The toxicity of Compound A was investigated by oral or intraperitoneal administration to mice and rats.
As shown in the results, it has extremely low toxicity, and no problematic side effects were observed when administering high doses.
表１ 急性毒性
〈発明の効果〉
本発明の医薬は以下の実施例に示すようにダラム陰性菌
、ダラム陽性菌、真菌等の微生物に対し優れた抗菌活性
を示した。従って本発明の医薬は感染症用剤として優れ
たものである
以下、本発明を更に実施例により説明するが、本発明は
これらに限定されるものではない。Table 1 Acute Toxicity (Effects of the Invention) As shown in the Examples below, the pharmaceutical of the present invention exhibited excellent antibacterial activity against microorganisms such as Durum-negative bacteria, Durum-positive bacteria, and fungi. Therefore, the medicament of the present invention is excellent as a drug for infectious diseases.Hereinafter, the present invention will be further explained with reference to Examples, but the present invention is not limited thereto.
実施例１
日本化学療法学会指定の標準方法（菌接種量：１０６ｃ
ｅｌｌ／ｍｌ Ｊ７℃で１８時間培養）により化合物Ａ
の抗菌活性（ＭＩＣ）を検討した。結果を表１に示した
。Example 1 Standard method specified by the Japanese Society of Chemotherapy (bacteria inoculation amount: 106 c
Compound A
The antibacterial activity (MIC) of The results are shown in Table 1.
表 １
表１から明らかなように化合物Ａは優れた抗菌活性を示
した。Table 1 As is clear from Table 1, Compound A exhibited excellent antibacterial activity.
実施例２
臨床で分離されたＭＲ５Ａの７５株について化合物Ａの
抗菌活性を日本化学療法学会指定の標準方法（菌接種量
： １０’ｃｅｌｌ／ｍｌ、３７℃で１８時間培養）に
より検討し、化合物Ａの各濃度における上記７５株中で
の増殖が抑制された株数の割合（Ｃｕｍｕｌａｔｉｖｅ
ｐｅｒｃｅｎｔａｇｅ）を求めた。結果を表２に示した
。Example 2 The antibacterial activity of Compound A was examined for 75 clinically isolated MR5A strains using the standard method specified by the Japanese Society of Chemotherapy (bacteria inoculation amount: 10'cell/ml, cultured at 37°C for 18 hours). Percentage of the number of strains whose growth was suppressed among the 75 strains at each concentration of A (Cumulative
percentage) was calculated. The results are shown in Table 2.
表２
上表から明らかなように化合物Ａは臨床で分離されたＭ
Ｒ５Ａに対し、優れた抗菌活性を示した。Table 2 As is clear from the above table, Compound A is a clinically isolated M
It showed excellent antibacterial activity against R5A.
Claims (1)
２Ｈ）−オンまたはその生理学的許容塩を有効成分とす
る感染症用剤2-phenyl-1,2-benziisoselenazole-3 (
Agent for infectious diseases containing 2H)-one or its physiologically acceptable salt as an active ingredient
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63001068A JP2548267B2 (en) | 1988-01-06 | 1988-01-06 | Infectious disease agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63001068A JP2548267B2 (en) | 1988-01-06 | 1988-01-06 | Infectious disease agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01180825A true JPH01180825A (en) | 1989-07-18 |
| JP2548267B2 JP2548267B2 (en) | 1996-10-30 |
Family
ID=11491210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63001068A Expired - Fee Related JP2548267B2 (en) | 1988-01-06 | 1988-01-06 | Infectious disease agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2548267B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996033712A1 (en) * | 1995-04-25 | 1996-10-31 | Daiichi Pharmaceutical Co., Ltd. | Remedy for acquired immunodeficiency syndrome |
| JP2002034553A (en) * | 2000-07-24 | 2002-02-05 | Eiken Chem Co Ltd | Medium for screening mrsa |
| US7671211B1 (en) | 1999-03-31 | 2010-03-02 | Arne Holmgren | Substrates for thioredoxin reductase |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
-
1988
- 1988-01-06 JP JP63001068A patent/JP2548267B2/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996033712A1 (en) * | 1995-04-25 | 1996-10-31 | Daiichi Pharmaceutical Co., Ltd. | Remedy for acquired immunodeficiency syndrome |
| US7671211B1 (en) | 1999-03-31 | 2010-03-02 | Arne Holmgren | Substrates for thioredoxin reductase |
| JP2002034553A (en) * | 2000-07-24 | 2002-02-05 | Eiken Chem Co Ltd | Medium for screening mrsa |
| JP4583559B2 (en) * | 2000-07-24 | 2010-11-17 | 栄研化学株式会社 | Medium for MRSA screening |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2548267B2 (en) | 1996-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CHANTOT et al. | Antibacterial activity of roxithromycin: a laboratory evaluation | |
| KR101783573B1 (en) | Compositions and methods of treatment comprising ceftaroline | |
| EP0563844B1 (en) | Antimicrobial compositions and pharmaceutical preparations thereof | |
| Figueredo et al. | Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis | |
| JP5276653B2 (en) | Bactericidal anti-MRSA active pharmaceutical composition comprising carbapenems | |
| CN115518056A (en) | Use of nerolidol, nerol and geraniol for antibacterial purpose | |
| JPH01180825A (en) | Agent for infectious disease | |
| CN116617361A (en) | Application of Thymol in Preparation of MCR-1 Enzyme Inhibitor | |
| US3949077A (en) | Synergistic antibiotic compositions | |
| JP2629166B2 (en) | Antibacterial agent effective against methicillin-resistant Staphylococcus aureus | |
| US7119075B2 (en) | Use of herbal agents for potentiation of bioefficacy of anti infectives | |
| KR20200038435A (en) | Antibiotics composition for animals | |
| CN107789355B (en) | Compound pharmaceutical composition containing piperacillin and application thereof | |
| CN100425236C (en) | Use of cuminum cyminum extract and piperine for potentiaion of bioeffectacy of anti infectives | |
| US3156617A (en) | Therapeutic compositions of kanamycin 2-(para-tertiary-amylphenoxy)-n-butyrate | |
| Fu et al. | Synergistic activity of apalcillin and gentamicin in a combination therapy in experimental Pseudomonas bacteraemia of neutropenic mice | |
| Guillemin et al. | Activity of coumermycin against clinical isolates of staphylococci | |
| RU2195937C1 (en) | Combined antituberculosis preparation (rizobutol) | |
| WO1996008259A1 (en) | Synergistic antimicrobial composition | |
| CN106673989A (en) | Pharmaceutical composition as well as preparation method and application thereof | |
| US20020161003A1 (en) | Method and compositions for the eradication and control of methicillin-resistant staphylococcus aureus bacteria and the prevention of the development of antibiotic drug resistance in said bacteria | |
| CN114886879A (en) | Application of linalool, perillyl alcohol and perillaldehyde in antibiosis | |
| CN116808055A (en) | Method for resisting novel cryptococcus by combining sclareolide and amphotericin B | |
| EP0606506A1 (en) | Beta-lactamase resistant antibacterial composition | |
| Fu et al. | Therapeutic efficacy of cefpiramide and cefoperazone alone and in combination with gentamicin against pseudomonal infections in neutropenic mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |